摘要
目的观察地特胰岛素联合瑞格列奈治疗2型糖尿病的临床疗效。方法选取2016年1月至2017年7月建德市第一人民医院内分泌科收治的2型糖尿病患者100例为研究对象,采用随机数字表法将患者分成观察组和对照组,每组50例。对照组患者采用中性低精蛋白锌人胰岛素(诺和灵N)联合瑞格列奈治疗,观察组患者采用地特胰岛素联合瑞格列奈治疗,比较分析两组临床治疗效果。结果治疗后观察组的临床总有效率为96%,明显高于对照组(78%),差异有统计学意义(χ2=22.014,P<0.05)。两组治疗前生化指标水平差异均无统计学意义(t=0.125、1.225、0.322、0.123、0.142,均P>0.05),治疗后观察组各项指标水平均优于对照组,两组差异均有统计学意义(t=5.064、5.035、6.154、5.032、5.165,均P<0.05)。结论地特胰岛素联合瑞格列奈和传统的胰岛素联合瑞格列奈都可以降低2型糖尿病患者的血糖水平,但是前者联合使用的效果更好。
Objective To analyze the clinical effect of insulin detemir combined with repaglinide in the treatment of type 2 diabetes mellitus (T2DM). Methods From January 2016 to July 2017,100 patients with T2DM in the First People's Hospital of Jiande were randomly divided into the observation group and control group according to the digital table,with 50 cases in each group.The control group was treated by low neutral protamine zinc human insulin(N) and repaglinide,the observation group was treated by insulin detemir combined with repaglinide.The clinical treatment effect was compared between the two groups. Results The total effective rate of the observation group was 96%,which was significantly higher than 78% of the control group,the difference was statistically significant (χ2=22.014,P<0.05).Before treatment,the biochemical indicators between the two groups had no statistically significant differences(t=0.125,1.225,0.125,1.225,0.142,all P>0.05).After treatment,the biochemical indicators of the observation group were better than those of the control group (t=5.064,5.035,5.064,5.035,5.165,all P<0.05). Conclusion Though insulin detemir combined with repaglinide and traditional insulin combined with repaglinide can lower blood glucose in patients with T2DM,but the former combination effect is better.
作者
王存解
冯迎儿
Wang Cunjie;Feng Yinger(Department of Endocrinology,the First People's Hospital of Jiande,Jiande,Zhejiang 311600,China)
出处
《中国基层医药》
CAS
2018年第24期3155-3157,共3页
Chinese Journal of Primary Medicine and Pharmacy
关键词
糖尿病
2型
血糖
血红蛋白A
糖基化
地特胰岛素
瑞格列奈
疗效比较研究
Diabetes mellitus,type 2
Blood glucose
Hemoglobin A,glycosylated
Insulin delta
Repaglinide
Comparative effectiveness research
